HUE041329T2 - Támogatott részecskeméret-csökkentési eljárás - Google Patents

Támogatott részecskeméret-csökkentési eljárás

Info

Publication number
HUE041329T2
HUE041329T2 HUE15702834A HUE15702834A HUE041329T2 HU E041329 T2 HUE041329 T2 HU E041329T2 HU E15702834 A HUE15702834 A HU E15702834A HU E15702834 A HUE15702834 A HU E15702834A HU E041329 T2 HUE041329 T2 HU E041329T2
Authority
HU
Hungary
Prior art keywords
particle size
reduction process
size reduction
assisted particle
assisted
Prior art date
Application number
HUE15702834A
Other languages
English (en)
Hungarian (hu)
Inventor
Eunice Costa
Marcio TEMTEM
Luis Sobral
Constança Cacela
Peter Villax
Original Assignee
Hovione Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Holding Ltd filed Critical Hovione Holding Ltd
Publication of HUE041329T2 publication Critical patent/HUE041329T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thermistors And Varistors (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE15702834A 2014-01-28 2015-01-27 Támogatott részecskeméret-csökkentési eljárás HUE041329T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT10743314A PT107433B (pt) 2014-01-28 2014-01-28 Processo de redução e controlo do tamanho de partícula

Publications (1)

Publication Number Publication Date
HUE041329T2 true HUE041329T2 (hu) 2019-05-28

Family

ID=52450514

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15702834A HUE041329T2 (hu) 2014-01-28 2015-01-27 Támogatott részecskeméret-csökkentési eljárás

Country Status (11)

Country Link
US (1) US10328027B2 (enExample)
EP (1) EP3096738B1 (enExample)
JP (1) JP6499187B2 (enExample)
AU (1) AU2015212618B2 (enExample)
CA (1) CA2938071A1 (enExample)
DK (1) DK3096738T3 (enExample)
ES (1) ES2702643T3 (enExample)
HU (1) HUE041329T2 (enExample)
IL (1) IL246989A0 (enExample)
PT (1) PT107433B (enExample)
WO (1) WO2015114320A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN110361307B (zh) * 2019-08-15 2022-04-01 安徽工程大学 一种利用粒度分布特征值判断稻米新陈度的方法
EP3868842B1 (en) 2020-02-19 2023-06-07 University of Limerick Particle coating method
GB202002325D0 (en) 2020-02-19 2020-04-01 Univ Limerick Particle coating method
WO2022170027A1 (en) * 2021-02-04 2022-08-11 Edenbridge Pharmaceuticals, LLC Inhaled ivermectin
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6379459B1 (en) * 2000-10-24 2002-04-30 The United States Of America As Represented By The Secretary Of The Interior Crystallization of powders having uniform particle sizes by Ostwald ripening at large levels of supersaturation
CN101453986A (zh) 2006-03-14 2009-06-10 默克公司 通过微研磨和在微晶种上结晶生产结晶有机微粒组合物的方法和设备及其应用
EP2077903A2 (en) * 2006-10-03 2009-07-15 Ranbaxy Laboratories, Ltd. Process for the preparation of form i and form ii of ritonavir
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
CA2707594C (en) 2007-12-13 2015-08-18 Novartis Ag Process for preparing particulates of crystalline drug substance
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
PT106237B (pt) * 2012-03-30 2015-03-19 Hovione Farmaci Ncia S A Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas

Also Published As

Publication number Publication date
JP2017504637A (ja) 2017-02-09
PT107433B (pt) 2018-12-04
AU2015212618A1 (en) 2016-09-15
PT107433A (pt) 2015-07-28
US20160346206A1 (en) 2016-12-01
CA2938071A1 (en) 2015-08-06
AU2015212618B2 (en) 2018-08-02
IL246989A0 (en) 2016-09-29
ES2702643T3 (es) 2019-03-04
JP6499187B2 (ja) 2019-04-10
DK3096738T3 (en) 2019-01-21
EP3096738A1 (en) 2016-11-30
EP3096738B1 (en) 2018-09-26
WO2015114320A1 (en) 2015-08-06
US10328027B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
IL246989A0 (en) A controlled process to reduce particle size
GB201405614D0 (en) Particles
GB201413701D0 (en) Process
GB201417076D0 (en) Process
GB201405800D0 (en) Process
GB201405210D0 (en) Process
GB201504782D0 (en) Process
GB201415862D0 (en) Process
GB201404468D0 (en) Process
GB201413340D0 (en) Process
GB201412841D0 (en) Particles
GB201402950D0 (en) Process
GB2524136B (en) Process
GB201420285D0 (en) Process
GB201409126D0 (en) Process
GB201400137D0 (en) Process
PL3227246T3 (pl) Sposób kalcynowania tlenowego
GB201412406D0 (en) Process
SG11201610471UA (en) Process
GB201420111D0 (en) Process
GB201414292D0 (en) Process
GB201411627D0 (en) Process
GB2538692B (en) Process
GB201415972D0 (en) Process
GB201412656D0 (en) Process